V5 tag antibody and application thereof

CN118909128AActive Publication Date: 2024-11-08CENT SOUTH UNIV
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202410979210.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-22
Publication Date
2024-11-08
Estimated Expiration
2044-07-22

AI Technical Summary

Technical Problem

[0005]针对现有技术的以上缺陷或改进需求,本发明提供了一种V5标签抗体及其应用,其目的在于以猿猴病毒5(SV5)副粘病毒P和V蛋白上的氨基酸残基GKPIPNPLLGLDST(95-108)的合成肽与KLH偶联作为抗原,免疫刺激小鼠产生抗体,获取其免疫脾细胞与SP2/0-Ag14骨髓瘤融合,筛选获得一株抗体效价最高(1.96×104)的杂交瘤细胞株,以此制备V5标签单克隆抗体,通过该抗体可变区基因克隆及测序,获得该抗体重链和轻链的氨基酸序列,以此为基础可制备V5标签重组抗体,由此解决现有V5标签抗体种类较少,价格昂贵的技术问题

Benefits of technology

[0035] The present invention uses the synthetic peptide of the amino acid residue GKPIPNPLLGLDST (95-108) on the P and V proteins of simian virus 5 (SV5) paramyxovirus coupled with KLH as an antigen to immunostimulate mice to produce antibodies and obtain immune splenocytes. Hybridoma technology was used to prepare and screen V5 tag monoclonal antibodies with high titers. The experimental results showed that the potency of the screened V5 tag monoclonal antibodies was as high as 2.07×10 6 (Ascites antibody), affinity K D It is 1.425E-8 and has high activity, and can be used to detect, separate and purify target proteins labeled with V5 tags, especially for detecting target proteins without specific antibodies or other probes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909128A_ABST
    Figure CN118909128A_ABST
Patent Text Reader

Abstract

The invention relates to a V5 tag antibody and application thereof. The antibody comprises a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2 and a light chain CDR3, the amino acid sequence of the heavy chain CDR1 is as shown in SEQ ID NO: 1; the amino acid sequence of the heavy chain CDR2 is as shown in SEQ ID NO: 2; the amino acid sequence of the heavy chain CDR3 is as shown in SEQ ID NO: 3; the amino acid sequence of the light chain CDR1 is as shown in SEQ ID NO: 4; the amino acid sequence of the light chain CDR2 is as shown in SEQ ID NO: 5; the amino acid sequence of the light chain CDR3 is as shown in SEQ ID NO: 6; the titer of the ascites antibody can reach 2.07 * 10 < 6 >, the affinity of the purified antibody reaches 1.425 E-8, and the antibody is high in activity and has great application potential.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and more specifically to a V5 tag antibody and application thereof. Background Art

[0002] Epitope tagging is a method of recombining proteins through genetic modification during the cloning process, which is used to detect and / or purify expressed proteins. Epitope tags can locate gene products in a variety of cell types, study the topological structure of proteins and their complexes, identify related proteins, and are especially used to characterize newly identified, low-abundance or poorly immunogenic proteins in the absence of protein-specific antibodies. Epitope tags are usually used to bind to the C or N terminus of recombinant proteins for epitope tagging. The V5 tag is derived from a small epitope (Pk) on the P and V proteins of the paramyxovirus simian virus 5 (SV5). The commonly used V5 tag contains all 14 amino acids (GKPIPNPLLGLDST), but a shorter 9-amino acid sequence (IPNPLLGLD) can also be used.

[0003] The V5 tag antibody is an antibody used to detect and purify V5-tagged proteins. It has the advantages of high specificity, can recognize the V5 epitope on the C-terminus or N-terminus of the recombinant protein, and is not affected by the surrounding amino acid sequence. It is an effective tool for detecting recombinant proteins containing the V5 epitope. It is often used to detect and purify target proteins with V5 tags, especially in the absence of specific antibodies or other probes. V5 tag antibodies can be used in a variety of applications, such as enzyme-linked immunosorbent assay (ELISA), Western blotting (WB), flow cytometry (Flow Cytometry), immunoprecipitation (IP) and immunocytochemistry / immunofluorescence (ICC / IF).

[0004] Although V5 tag antibodies have the advantages of high specificity and versatility, providing researchers with effective tools to explore protein functions and their interactions, the types of V5 tag monoclonal antibodies currently available on the market are limited and expensive. Therefore, the development of new V5 tag monoclonal antibodies has great application potential, especially in the immunoadsorption and purification of recombinant proteins, which is expected to expand its wide application prospects. Summary of the invention

[0005] In view of the above defects or improvement needs of the prior art, the present invention provides a V5 tag antibody and its application, the purpose of which is to use a synthetic peptide of amino acid residues GKPIPNPLLGLDST (95-108) on the P and V proteins of simian virus 5 (SV5) paramyxovirus coupled with KLH as an antigen, immunostimulate mice to produce antibodies, obtain immune spleen cells and fuse them with SP2 / 0-Ag14 myeloma, and screen and obtain an antibody with the highest titer (1.96×10 4 ) hybridoma cell line is used to prepare V5 tag monoclonal antibody, and the amino acid sequence of the antibody heavy chain and light chain is obtained by cloning and sequencing the variable region gene of the antibody. Based on this, V5 tag recombinant antibody can be prepared, thereby solving the technical problem that the existing V5 tag antibodies are few in variety and expensive.

[0006] To achieve the above object, according to one aspect of the present invention, a V5 tag antibody is provided, which includes three heavy chain complementary determining regions: heavy chain CDR1, heavy chain CDR2 and heavy chain CDR3, and three light chain complementary determining regions: light chain CDR1, light chain CDR2 and light chain CDR3;

[0007] The heavy chain CDR1 is the amino acid sequence SYSIH shown in SEQ ID NO: 1;

[0008] The heavy chain CDR2 is the amino acid sequence YINPASGYSAYNENFKB shown in SEQ ID NO:2;

[0009] The heavy chain CDR3 is the amino acid sequence DKFYAYDY shown in SEQ ID NO: 3;

[0010] The light chain CDR1 is the amino acid sequence RASQSIVHKNGNTYLD shown in SEQ ID NO:4;

[0011] The light chain CDR2 is the amino acid sequence RVAQKFS shown in SEQ ID NO:5;

[0012] The light chain CDR3 is the sequence FNASHVPYT shown in SEQ ID NO:6.

[0013] Preferably, the V5 tag antibody, wherein FR1-4 in the heavy chain variable region of the antibody is the following amino acid sequence:

[0014] comprising or consisting of the amino acid sequence shown in SEQ ID NO: 7, 8, 9, 10,

[0015] or a sequence having at least 80%, 85%, 90% identity to the sequence shown in SEQ ID NO: 7, 8, 9, 10,

[0016] Or a sequence having one or more amino acid mutations compared to the amino acid sequence shown in SEQ ID NO: 7, 8, 9, 10.

[0017] Preferably, in the V5-tagged antibody, FR1-4 in the heavy chain variable region are the following amino acid sequences in sequence:

[0018] The amino acid sequences shown in SEQ ID NOs: 7, 8, 9, 10,

[0019] or a sequence having at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence shown in SEQ ID NO: 7, 8, 9, 10,

[0020] Or an amino acid sequence having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid mutations compared to the amino acid sequence shown in SEQ ID NO: 7, 8, 9, 10; the amino acid mutation is a conservative mutation, including substitution, insertion or deletion.

[0021] Preferably, the V5 tag antibody, wherein FR1-4 in the light chain variable region of the antibody is the following amino acid sequence:

[0022] comprising or consisting of the amino acid sequence shown in SEQ ID NO: 11, 12, 13, 14,

[0023] or a sequence having at least 80%, 85%, 90% identity to the sequence shown in SEQ ID NO: 11, 12, 13, 14,

[0024] Or a sequence having one or more amino acid mutations compared to the amino acid sequence shown in SEQ ID NO: 11, 12, 13, 14.

[0025] Preferably, in the V5-tagged antibody, FR1-4 in the light chain variable region are the following amino acid sequences in sequence:

[0026] The amino acid sequences shown in SEQ ID NOs: 11, 12, 13, 14,

[0027] or a sequence having at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence shown in SEQ ID NO: 11, 12, 13, 14,

[0028] Or an amino acid sequence having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid mutations compared to the amino acid sequence shown in SEQ ID NO: 11, 12, 13, 14; the amino acid mutation is a conservative mutation, including substitution, insertion or deletion.

[0029] Preferably, the V5 tag antibody, the antibody, its heavy chain amino acid sequence is shown in SEQ ID NO:15, and the light chain amino acid sequence is shown in SEQ ID NO:16.

[0030] According to another aspect of the present invention, a biological material containing a nucleic acid sequence encoding the V5 tag antibody of the present invention is also provided, wherein the biological material includes an expression vector, an expression cassette, a host cell, an engineered bacterium or a hybridoma cell line.

[0031] According to another aspect of the present invention, there is also provided a use of the V5 tag antibody of the present invention in detecting, separating and purifying a V5-tagged target protein.

[0032] Preferably, the use is applied to enzyme-linked immunosorbent assay, immunoblotting, flow cytometry, immunoprecipitation, and / or immunocytochemistry / immunofluorescence.

[0033] According to another aspect of the present invention, a target protein detection kit is provided, which comprises the V5 tag antibody as described in the present invention.

[0034] In general, compared with the prior art, the above technical solution conceived by the present invention can achieve the following beneficial effects due to the new V5 tag antibody provided by the present invention:

[0035] The present invention uses a synthetic peptide of amino acid residues GKPIPNPLLGLDST (95-108) on the P and V proteins of simian virus 5 (SV5) paramyxovirus coupled with KLH as an antigen, immunizes mice to produce antibodies, obtains immune spleen cells, and prepares and screens high-titer V5 tag monoclonal antibodies through hybridoma technology. The experimental results show that the titer of the screened V5 tag monoclonal antibodies is as high as 2.07×10 6 (ascites antibody), affinity K D The activity is 1.425E-8 and it is highly active, and can be used to detect, separate and purify target proteins labeled with V5 tags, especially for detecting target proteins without specific antibodies or other probes. BRIEF DESCRIPTION OF THE DRAWINGS

[0036] Figure 1 are the heavy chain and light chain amino acid sequences of the V5 tag monoclonal antibody screened in Example 1;

[0037] Figure 2This is the activity measurement result of the V5 tag monoclonal antibody in Example 2. DETAILED DESCRIPTION

[0038] In order to further explain the technical means and effects adopted by the present invention to achieve the predetermined invention purpose, the specific implementation mode, structure, characteristics and effects of the present invention are described in detail below in combination with the accompanying drawings and preferred embodiments.

[0039] The term "amino acid" refers to a naturally occurring or non-naturally occurring carboxyl α-amino acid. The term "amino acid" as used in the present application may include naturally occurring amino acids and non-naturally occurring amino acids. Naturally occurring amino acids include alanine (three letter code: Ala, single letter code: A), arginine (Arg, R), asparagine (Asn, N), aspartic acid (Asp, D), cysteine ​​(Cys, C), glutamine (Gln, Q), glutamic acid (Glu, E), glycine (Gly, G), histidine (His, H), isoleucine (Ile, I), leucine (Leu, L), lysine (Lys, K), methionine (Met, M), phenylalanine (Phe, F), proline (Pro, P), serine (Ser, S), threonine (Thr, T), tryptophan (Trp, W), tyrosine (Tyr, Y), and valine (Val, V). Non-naturally occurring amino acids include, but are not limited to, α-aminoadipic acid, aminobutyric acid, citrulline, homocitrulline, homoleucine, homoarginine, hydroxyproline, norleucine, pyridylalanine, sarcosine, and the like.

[0040] In the present invention, peptides, polypeptides, and proteins are not strictly distinguished and can be used interchangeably in some cases. Generally, they refer to polymers composed of amino acids connected by peptide bonds, whether naturally occurring or synthetic. Polypeptides may also contain non-amino acid components, such as carbohydrate groups, metal ions, or carboxylates. Non-amino acid components may be added by cells expressing the polypeptide and may vary with cell types. Polypeptides are defined in the present invention with respect to their amino acid backbone structure or nucleic acids encoding them. For example, the addition of carbohydrate groups is usually not specified, but it may be present. All polypeptide sequences are written according to the generally accepted convention, with the α-N-terminal amino acid residue on the left and the α-C-terminal amino acid residue on the right. When used in the present invention, the term "N-terminal" refers to the free α-amino group of an amino acid in a polypeptide, and the term "C-terminal" refers to the free α-carboxylic acid end of an amino acid in a polypeptide. A polypeptide ending with a certain group at the N-terminal refers to a polypeptide carrying a group on the α-amino nitrogen of the N-terminal amino acid residue. An amino acid ending with a certain group at the N-terminal refers to an amino acid carrying a group on the α-amino nitrogen.

[0041] The present invention couples a synthetic peptide of amino acid residues GKPIPNPLLGLDST (95-108) on the P and V proteins of simian virus 5 (SV5) paramyxovirus with KLH as an antigen, immunizes mice to produce antibodies, obtains immune spleen cells of mice, and then fuses with mouse myeloma cells SP2 / 0-Ag14 to obtain hybridoma cells, and obtains multiple stable V5-tagged hybridoma cells through cell culture and screening. The selected hybridoma cell lines are injected into the peritoneal cavity of mice to screen the ascites antibody (monoclonal antibody) with the highest titer, and the antibody gene is detected, and its heavy chain amino acid sequence is shown in SEQ ID NO: 15, and the light chain amino acid sequence is shown in SEQ ID NO: 16, and the complementary determining regions of the heavy chain and light chain of the antibody are obtained, wherein the complementary determining regions of the heavy chain of the antibody are as follows:

[0042] CDR1:SYSIH;

[0043] CDR2: YINPASGYSAYNENFKB;

[0044] CDR3:DKFYAYDY;

[0045] The complementarity determining regions of the light chain are as follows:

[0046] CDR1:RASQSIVHKNGNTYLD;

[0047] CDR2: RVAQKFS;

[0048] CDR3: FNASHVPYT;

[0049] V5-tagged recombinant antibodies were prepared according to the obtained antibody variable region gene sequences.

[0050] Based on this, the present invention provides a V5 tag antibody, which comprises VHCDR1, VHCDR2 and VHCDR3 with amino acid sequences as shown in SEQ ID NO:1-3, or consists of them; and comprises VLCDR1, VLCDR2 and VLCDR3 with amino acid sequences as shown in SEQ ID NO:4-6, or consists of them.

[0051] The amino acid sequence shown in SEQ ID NO: 1 is SYSIH, the amino acid sequence shown in SEQ ID NO: 2 is YINPASGYSAYNENFKB, and the amino acid sequence shown in SEQ ID NO: 3 is DKFYAYDY;

[0052] The amino acid sequence shown in SEQ ID NO:4 is RASQSIVHKNGNTYLD; the amino acid sequence shown in SEQ ID NO:5 is RVAQKFS; and the amino acid sequence shown in SEQ ID NO:6 is FNASHVPYT.

[0053] Preferably, in the antibody, FR1-4 in the heavy chain variable region are the following amino acid sequences in sequence:

[0054] comprising or consisting of the amino acid sequence shown in SEQ ID NO: 7, 8, 9, 10,

[0055] Or a sequence having at least 80%, 85%, or 90% identity to the sequence shown in SEQ ID NO: 7, 8, 9, or 10;

[0056] Or a sequence having one or more amino acid mutations compared to the amino acid sequence shown in SEQ ID NO: 7, 8, 9, 10;

[0057] More preferably, in the antibody, FR1-4 in the heavy chain variable region are the following amino acid sequences:

[0058] The amino acid sequences shown in SEQ ID NOs: 7, 8, 9, 10;

[0059] Or a sequence having at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the sequence shown in SEQ ID NO:7, 8, 9, 10;

[0060] Or it has 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid mutations compared with the sequence shown in SEQ ID NO: 7, 8, 9, 10; the amino acid mutation is a conservative mutation, preferably a substitution, insertion or deletion.

[0061] Furthermore, in the antibody, FR1-4 in the light chain variable region are the following amino acid sequences in sequence:

[0062] comprising or consisting of the amino acid sequence shown in SEQ ID NO: 11, 12, 13, 14,

[0063] Or a sequence having at least 80%, 85%, 90% identity to the sequence shown in SEQ ID NO: 11, 12, 13, 14; preferably a sequence having at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the sequence shown in SEQ ID NO: 11, 12, 13, 14;

[0064] Or a sequence having one or more amino acid mutations compared to the amino acid sequence shown in SEQ ID NO: 11, 12, 13, 14; preferably a sequence having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid mutations compared to the amino acid sequence shown in SEQ ID NO: 11, 12, 13, 14; the amino acid mutation is a conservative mutation, preferably a substitution, insertion or deletion.

[0065] In some embodiments, the V5 tag antibody has a heavy chain amino acid sequence as shown in SEQ ID NO:15, and a light chain amino acid sequence as shown in SEQ ID NO:16.

[0066] In some embodiments, the present invention also provides a nucleic acid sequence encoding a V5 tag antibody or an antibody fragment thereof as described in the present invention. In the present invention, the nucleic acid sequence comprises a conservatively substituted variant thereof (e.g., a substitution of a degenerate codon) and a complementary sequence. The terms "nucleic acid" and "polynucleotide" are synonymous and include genes, cDNA molecules, mRNA molecules, and fragments thereof such as oligonucleotides.

[0067] In some embodiments, the present invention further provides a biological material containing a nucleic acid sequence encoding the V5 tag antibody of the present invention, wherein the biological material includes an expression vector, an expression cassette, a host cell, an engineered bacterium or a hybridoma cell line.

[0068] The nucleic acid sequence is operably linked to at least one regulatory sequence. "Operably linked" means that the coding sequence is linked to the regulatory sequence in a manner that allows the expression of the coding sequence. The regulatory sequence is selected to direct the expression of the target protein in a suitable host cell and includes a promoter, an enhancer and other expression control elements.

[0069] In addition, the present invention also provides a use of the V5 tag antibody of the present invention in detecting, separating and purifying a target protein tagged with a V5 epitope.

[0070] The applications include enzyme linked immunosorbent assay (ELISA), Western blotting (WB), flow cytometry (Flow Cytometry), immunoprecipitation (IP) and immunocytochemistry / immunofluorescence (ICC / IF).

[0071] The present invention also provides a detection kit comprising the V5 tag antibody of the present invention.

[0072] The detection kit is used for detecting and / or purifying a target protein containing a V5 tag.

[0073] The following are examples

[0074] Example 1 Preparation and screening of V5-tagged monoclonal antibodies

[0075] (1) Antigen Immunization

[0076] In this example, a synthetic peptide of amino acid residues GKPIPNPLLGLDST (95-108) from the P and V proteins of simian virus 5 (SV5) paramyxovirus was coupled with KLH and injected subcutaneously into BALB / c mice at a dose of 0.15 mL. 14 days after the first immunization, booster immunization was performed. After the fourth booster immunization, tail blood was collected for testing, and the titer reached the fusion requirement. Three days before fusion, immunization was continued once.

[0077] (2) Preparation of hybridoma cell lines

[0078] (1) Preparation of feeder cells

[0079] BALB / c mouse peritoneal macrophages were used as feeder cells. After killing the mice, disinfecting and fixing the body surface, the abdomen was cut open to expose the peritoneum, 5 mL of RPMI 1640 basal culture medium was injected, and the abdomen was gently massaged for 1 minute, and then the injected culture medium was aspirated. Centrifuge at 1000 rpm for 5 minutes and remove the supernatant. Resuspend with RPMI 1640 culture medium containing HAT, adjust the concentration to 1×105 cells / mL, add the cells to a 96-well cell culture plate, 150 μL / well, and culture overnight at 37°C and 5% CO2.

[0080] (2) Preparation of immune spleen cells

[0081] Three days after the last immunization, the spleen of the mouse was removed under sterile conditions, placed in a plate, washed with RPMI1640 basal culture medium, ground and filtered on a nylon membrane to prepare a spleen cell suspension. After centrifugation, the supernatant was removed and resuspended with RPMI 1640 basal culture medium. This was repeated three times to obtain immune spleen cells and counted.

[0082] (3) Preparation of myeloma cells

[0083] Mouse myeloma cells SP2 / 0-Ag14 were selected with 8-azaguanine and cultured to the logarithmic growth phase. Two large bottles were used to prepare cell suspensions. The supernatant was removed after centrifugation and the cells were resuspended in RPMI 1640 basal culture medium. The process was repeated three times to obtain myeloma cells, which were then counted.

[0084] (4) Cell fusion and HAT selection of hybridomas

[0085] Mix the prepared myeloma cells with immune spleen cells at a ratio of 1:10, add RPMI 1640 basal culture medium, centrifuge at 1200rpm for 10 minutes, and remove the supernatant. Mix the cells, slowly add 1mL50% PEG 1500 for fusion, and add 15mL RPMI 1640 basal culture medium after fusion for 1 minute to terminate cell fusion. Centrifuge at 1000rpm for 10 minutes and remove the supernatant. Gently resuspend with 50mL RPMI 1640 culture medium, inoculate evenly in 10 96-well plates, 50μL / well, 37℃, 5% CO2 culture. Culture to the sixth day, change HAT culture medium (complete RPMI 1640 culture medium containing HAT), aspirate 1 / 2 of the old culture medium in the culture well each time, replace with new solution, and change twice.

[0086] (5) Hybridoma cell screening and cloning

[0087] Dilute V5 antigen to 1 μg / mL with 0.05M pH 9.6 carbonate buffer solution, add to 96-well plate, and incubate at 37°C for 2 hours. Add 0.02M PBS with pH 7.2 containing 10% calf serum or 1% skim milk powder to 96-well plate, 0.15mL / well, block at 37°C for 2 hours for detection. On the 7th day after fusion, take 0.1mL of cell supernatant to 96-well plate, incubate at 37°C for 30 minutes, wash 6 times with water, add secondary antibody, incubate at 37°C for 30 minutes. After washing, add 100μL of 0.1% (M / V) o-phenylenediamine, 0.1% (V / V) hydrogen peroxide, pH 5.0 citric acid phosphate buffer to each well, incubate at 37°C for 15 minutes; add dilute sulfuric acid solution, 50μL per well, and measure the absorbance at 450nm.

[0088] In a 96-well culture plate, the antibody-secreting positive cell wells were cloned using the limiting dilution method at 1 cell / well, and the positive wells were screened and cloned three times in succession. After expansion culture, the cells were cryopreserved in a culture medium containing 10% DMSO in steps, and the cell density was 1×106 / mL. A total of five stable V5-tagged hybridoma cell lines were obtained, named A, B, C, D, and E.

[0089] (3) Preparation of V5 tag monoclonal antibody

[0090] Select healthy BALB / c mice aged 6 to 8 weeks and inject 0.5 mL of pristane intraperitoneally into each mouse. Ten days later, inject 1×10 6hybridoma cells. 7-10 days after inoculation of cells, closely observe the health status and ascites signs of the animals. When ascites is as much as possible and before the mice die, kill the mice and use a dropper to suck the ascites into a test tube. Generally, 5-10 mL of ascites can be obtained from one mouse. Collect the ascites, centrifuge to obtain the supernatant, and store it in a -20℃ refrigerator. Take the ascites supernatant, dilute it with 3 times the volume of PBS, and filter it with filter paper. Add the resulting filtrate to the protein G affinity chromatography column equilibrated with PBS at a flow rate of 1 mL / min. Then wash the substances not adsorbed by protein G with PBS at a flow rate of 1 mL / min until the absorbance value at 280 nm reaches the baseline. Then elute and recover the antibody with a 0.1M glycine eluent at pH 2.5. The recovered solution is neutralized with a 0.1M Tris solution at pH 8.8, and the antibody concentration is adjusted to an appropriate concentration by ultrafiltration, and stored in aliquots at -20℃.

[0091] (4) Screening of V5 tag antibodies

[0092] The titers of the above five hybridoma cells and secreted ascites antibodies were detected by indirect ELISA to screen the cell line with the highest titer. The specific experimental steps are as follows:

[0093] (1) Coating: Dilute V5 antigen to 1 μg / mL, add 100 μL / well to the ELISA plate, and incubate at 37°C for 2 hours or at 4°C overnight;

[0094] (2) Wash the plate 5 times using a plate washer, injecting 350 μL of wash solution into each well each time, leaving it for 20 seconds; finally, pat it dry;

[0095] (3) Wash off the coating solution with washing solution, block with blocking solution, 150 μL per well, and place at 37°C for 1.5-2 hours;

[0096] (4) Wash the plate 5 times with a plate washer, inject 350 μL of wash solution into each well each time, leave for 20 seconds, and pat dry.

[0097] (5) Add samples: Add cell culture supernatant and ascites diluted into different gradients to the ELISA plate coated with V5 antigen, 100 μL / well, and react at 37°C for 1 hour (do negative control wells and positive control wells at the same time);

[0098] (6) Wash the plate 5 times with a plate washer, inject 350 μL of wash solution into each well each time, leave for 20 seconds, and pat dry.

[0099] (7) Add horseradish peroxidase-labeled goat anti-mouse IgG enzyme-labeled secondary antibody (diluted 6000 times with blocking solution), 100 μL / well, and react at 37°C for 1 hour;

[0100] (8) Wash the plate 5 times with a plate washer, inject 350 μL of wash solution into each well each time, leave for 20 seconds, and pat dry.

[0101] (9) Add TMB colorimetric solution: prepare immediately before use, 100 μL / well, react at 37°C in the dark for 30 min;

[0102] (10) Termination of reaction: Add 2 M sulfuric acid to each reaction well, 50 μL / well;

[0103] (11) Microplate reader reading: 450nm, 630nm wavelength measurement.

[0104] The final measurement results are as follows:

[0105] Table 1 Comparison of the titers of various cell lines

[0106] Cell lines Hybridoma cell culture supernatant titer Ascites antibody titer 4F6 <![CDATA[2.37×10 3 ]]> <![CDATA[2.83×10 5 ]]> 7C5 <![CDATA[2.71×10 3 ]]> <![CDATA[3.16×10 5 ]]> 5D8 <![CDATA[1.96×10 4 ]]> <![CDATA[2.07×10 6 ]]> 3E7 <![CDATA[3.34×10 3 ]]> <![CDATA[4.74×10 5 ]]> 6B10 <![CDATA[1.82×10 3 ]]> <![CDATA[2.71×10 5 ]]>

[0107] From the results in Table 1, it can be seen that the V5 antibody secreted by cell line 5D8 has the highest titer, so the cell line 5D8 with the highest titer was screened out.

[0108] (5) Antibody variable region gene cloning and sequencing

[0109] Total RNA was extracted from the hybridoma cell line 5D8 secreting the V5 monoclonal antibody, and the first-strand cDNA was synthesized using the SMARTERTM RACEcDNA Amplification Kit and the SMARTER II A Oligonucleotide and 5'-CDS primer in the kit. The first-strand cDNA product obtained was used as a PCR amplification template. The Light Chain gene was amplified using Universal Primer A Mix (UPM), Nested Universal Primer A (NUP) and mIgG CKR primers, and the Heavy Chain gene was amplified using Universal Primer A Mix (UPM), Nested Universal Primer A (NUP) and mIgG CHR primers. The primer pair of the Light Chain amplified a target band of about 0.7 kb, and the primer pair of the Heavy Chain amplified a target band of about 1.5 kb. The product was purified and recovered by agarose gel electrophoresis, and then inserted into the pMD-18T vector after A addition reaction with rTaq DNA polymerase, and transformed into DH5α competent cells. After the colonies grew, 4 clones of Heavy Chain and Light Chain gene clones were taken and sent to Qingke Company for sequencing. The amino acid sequences of the heavy chain and light chain are shown in SEQ ID NO: 15 and SEQ ID NO: 16, respectively. The specific amino acid sequences are shown in Figure 1 As shown; after analysis, the complementarity determining region of the heavy chain:

[0110] CDR1:SYSIH;

[0111] CDR2: YINPASGYSAYNENFKB;

[0112] CDR3:DKFYAYDY;

[0113] Complementarity determining region of light chain:

[0114] CDR1:RASQSIVHKNGNTYLD;

[0115] CDR2: RVAQKFS;

[0116] CDR3: FNASHVPYT.

[0117] Example 2 Monoclonal Antibody Affinity Analysis and Activity Determination

[0118] (1) Comparison of affinity of purified monoclonal antibodies with different V5 tags

[0119] V5 tag monoclonal antibody was prepared and purified, and the data were determined by indirect enzyme immunoassay in the same way as activity identification. The coating concentration included four gradients of 1μg / mL, 0.5μg / mL, 0.25μg / mL, and 0.125μg / mL; the antibody was diluted 2 times from 1000ng / mL to 0.97656ng / mL for loading. The OD values ​​corresponding to different antibody concentrations under different coating concentrations were obtained. At the same coating concentration, with the antibody concentration as the horizontal axis and the OD value as the vertical axis, a logarithmic plot was made, and the antibody concentration at 50% of the maximum OD value was calculated according to the fitting equation; the reciprocal of the affinity constant was calculated by substituting the formula: K = (n-1) / (2*(n*Ab`-Ab)), where Ab and Ab` represent the antibody concentration at 50% of the maximum OD value under the corresponding coating concentration (Ag, Ag`), respectively, and n = Ag / Ag`; every two coating concentrations can be combined to calculate a K value, and finally six K values ​​can be obtained, and the average value is taken, and the reciprocal is the affinity constant KD.

[0120] The affinity of the purified V5 monoclonal antibody was analyzed, and the results are shown in Table 2.

[0121] Table 2 Affinity determination results of purified V5-tagged monoclonal antibodies

[0122] Sample name <![CDATA[K D ]]> 4F6 6.446E-7 7C5 4.375E-6 5D8 1.425E-8 3E7 9.837E-7 6B10 7.106E-6

[0123] As shown in Table 2, the affinity constant KD of the antibody secreted by the 5D8 hybridoma cell line is 1.425E-8, which is significantly better than that of the antibodies secreted by the other four hybridoma cell lines.

[0124] (2) Activity identification

[0125] Dilute V5 antigen to 1 μg / mL with 50 mM carbonate buffer coating solution for microplate coating, 100 μL per well, 4°C overnight; the next day, wash twice with PBST, pat dry; add blocking solution (20% BSA + 80% PBS), 120 μL per well, 37°C, 1h, pat dry; add diluted V5 monoclonal antibody 5D8, dilute 5 times from 1000 ng / mL, load, 100 μL / well, 37°C, 3 0min (partial supernatant 1h); wash 5 times with PBST washing solution, pat dry; add horseradish peroxidase labeled goat anti-mouse IgG, 100μL per well, 37℃, 30min; wash 5 times with PBST washing solution, pat dry; add urea peroxide (50μL / well), add tetramethylbenzidine (50μL / well), 10min; add dilute hydrochloric acid to terminate the reaction, 50μL / well; read the OD value at 450nm (reference 620nm) on the microplate reader. The results are shown in Table 3 and Figure 2 shown.

[0126] Table 3 Activity identification of purified V5-tagged monoclonal antibodies

[0127] Sample concentration ng / mL 1000 200 40 8 1.6 0.32 0 V5 tag antibody 5D8 3.324 2.017 0.856 0.198 0.142 0.079 0.015

[0128] From Table 3 and Figure 2 It can be seen that the sample concentration can be detected as low as 0.32ng / ml, indicating its high activity.

[0129] Example 3 Use of V5 tag antibody

[0130] The V5 tag antibody of the present invention was compared with the V5 tag antibody of other companies for anti-V5 monoclonal antibody affinity, and the specific implementation method is as follows:

[0131] The activity was identified by indirect enzyme immunoassay. Different V5 tag antibodies were used to determine different coating concentrations (1μg / ml, 0.5μg / ml, 0.25μg / ml, 0.125μg / ml) for experiments. Then, the antibody was diluted from an initial concentration of 1000ng / ml to 0.97656ng / ml by 2-fold gradient. The OD values ​​corresponding to different antibody concentrations at each coating concentration were recorded.

[0132] Next, at the same coating concentration, a logarithmic plot is made with the antibody concentration as the horizontal axis and the OD value as the vertical axis. The antibody concentration at 50% of the maximum OD value is calculated by fitting the equation. Then, the reciprocal of the affinity constant is calculated according to the formula K = (n-1) / (2*(n*Ab`-Ab)), where Ab and Ab` represent the antibody concentration at 50% of the maximum OD value under the corresponding coating concentration, and n is the coating concentration ratio (Ag / Ag`). Every two coating concentrations can be combined to calculate a K value, and finally six K values ​​are obtained. The average value is taken, and the reciprocal is the affinity constant KD.

[0133] Finally, the affinity analysis data of the purified anti-V5 monoclonal antibody are summarized in Table 4 below.

[0134] Table 4 Affinity determination results of anti-V5 monoclonal antibodies of different products

[0135]

[0136]

[0137] As shown in Table 4, the affinity of the anti-V5 monoclonal antibody of the present invention is significantly better than that of the V5 tag antibodies of the other three companies.

[0138] The above description is only a preferred embodiment of the present invention and does not limit the present invention in any form. Although the present invention has been disclosed as a preferred embodiment as above, it is not used to limit the present invention. Any technical personnel in this field can make some changes or modify the technical contents disclosed above into equivalent embodiments without departing from the scope of the technical solution of the present invention. However, any brief modifications, equivalent changes and modifications made to the above embodiments based on the technical essence of the present invention without departing from the content of the technical solution of the present invention are still within the scope of the technical solution of the present invention.

Claims

1. A V5 tag antibody, characterized in that Includes three heavy chain complementarity determining regions: heavy chain CDR1, heavy chain CDR2 and heavy chain CDR3, and three light chain complementarity determining regions: light chain CDR1, light chain CDR2 and light chain CDR3; The heavy chain CDR1 is the amino acid sequence SYSIH shown in SEQ ID NO: 1; The heavy chain CDR2 is the amino acid sequence YINPASGYSAYNENFKB shown in SEQ ID NO: 2; The heavy chain CDR3 is the amino acid sequence DKFYAYDY shown in SEQ ID NO: 3; The light chain CDR1 is the amino acid sequence RASQSIVHKNGNTYLD shown in SEQ ID NO:4; The light chain CDR2 is the amino acid sequence RVAQKFS shown in SEQ ID NO:5; The light chain CDR3 is the sequence FNASHVPYT shown in SEQ ID NO:

6.

2. The V5 tag antibody according to claim 1, characterized in that The antibody, in which FR1-4 in the heavy chain variable region are the following amino acid sequences: comprising or consisting of the amino acid sequence shown in SEQ ID NO: 7, 8, 9, 10, or a sequence having at least 80%, 85%, 90% identity to the sequence shown in SEQ ID NO: 7, 8, 9, 10, Or a sequence having one or more amino acid mutations compared to the amino acid sequence shown in SEQ ID NO: 7, 8, 9, 10.

3. The V5 tag antibody according to claim 2, characterized in that FR1-4 in the heavy chain variable region are the following amino acid sequences: The amino acid sequences shown in SEQ ID NOs: 7, 8, 9, 10, or a sequence having at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence shown in SEQ ID NO: 7, 8, 9, 10, Or an amino acid sequence having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid mutations compared to the amino acid sequence shown in SEQ ID NO: 7, 8, 9, 10; the amino acid mutation is a conservative mutation, including substitution, insertion or deletion.

4. The V5 tag antibody according to any one of claims 1 to 3, characterized in that: The antibody, in which FR1-4 in the light chain variable region are the following amino acid sequences: comprising or consisting of the amino acid sequence shown in SEQ ID NO: 11, 12, 13, 14, or a sequence having at least 80%, 85%, 90% identity to the sequence shown in SEQ ID NO: 11, 12, 13, 14, Or a sequence having one or more amino acid mutations compared to the amino acid sequence shown in SEQ ID NO: 11, 12, 13, 14.

5. The V5 tag antibody according to claim 4, characterized in that FR1-4 in the light chain variable region are the following amino acid sequences: The amino acid sequences shown in SEQ ID NOs: 11, 12, 13, 14, or a sequence having at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence shown in SEQ ID NO: 11, 12, 13, 14, Or an amino acid sequence having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid mutations compared to the amino acid sequence shown in SEQ ID NO: 11, 12, 13, 14; the amino acid mutation is a conservative mutation, including substitution, insertion or deletion.

6. The V5 tag antibody according to claim 5, characterized in that The antibody has a heavy chain amino acid sequence as shown in SEQ ID NO:15, and a light chain amino acid sequence as shown in SEQ ID NO:

16.

7. A biological material containing a nucleic acid sequence encoding the V5 tag antibody according to claim 6, characterized in that: The biological material includes expression vector, expression box, host cell, engineering bacteria or hybridoma cell line.

8. Use of the V5 tag antibody as claimed in claim 6 in detecting, separating and purifying a V5-tagged target protein.

9. The use according to claim 8, characterized in that For use in ELISA, immunoblotting, flow cytometry, immunoprecipitation, and / or immunocytochemistry / immunofluorescence.

10. A target protein detection kit, characterized in that: Comprising the V5 tag antibody as claimed in claim 6.

Citation Information

Patent Citations

  • Anti-Flag tag antibody and application thereof

    CN115028731A

  • Anti-His tag monoclonal antibody and application thereof

    CN116554338A

  • Anti-HA tag monoclonal antibody and application thereof

    CN116589572A